Fundraising FoxSisu Pharma
Chapel Hill, US · Founded 2019 · Delaware corporation
Find your way into Sisu Pharma
Sign up to see every warm intro you have to Sisu Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sisu Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Sisu Pharma develops therapeutics targeting Heat Shock Factor 1 (HSF1), using its HI-LiTe platform to create selective HSF1 degraders for oncology and HSF1 activators for neurodegenerative diseases. Its compounds are aimed at therapy-resistant cancers and other difficult-to-treat diseases.
Founders & leadership
Sisu Pharma was founded in 2019 by Sean E. O'Brien.
SE
Sean E. O'BrienFounder, Chief Executive OfficerSean O'Brien holds a PhD in Computational Chemistry and has over 20 years of experience in drug discovery, clinical development, and biotech entrepreneurship, including roles at Pfizer and Accelrys; he is founder and CEO of Sisu Pharma, which he co-founded alongside G4 Oncology and Trilogy Therapeutics.
JH
Jiaoti HuangNamed on SEC filing
SO
Sean O'BrienCo-founder and CEO
Board
MS
Michael Serrano-WuBoard director
Reported raises · per SEC filings
Form D private placements$1.7M disclosed across 1 round · 2020
▶$1.7MraisedJul 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.7MraisedJul 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jiaoti HuangExecutive Officer, Director, Promoter
- Dennis ThieleExecutive Officer, Director, Promoter
- Michael Serrano-WuDirector
- Sean O'BrienExecutive Officer, Director, Promoter
- Offering amount
- $4M
- Amount sold
- $1.7M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
SiSU Health GroupSiSU Health operates self-service health check stations that measure cardiometabolic health metrics including blood pressure, BMI, body fat percentage, and diabetes risk for preventive health screening. The company supplies hardware stations to organizations and offers a digital platform to support personalized health improvement.
UclahealthUCLA Health is a major academic health system providing patient care across five hospitals and 290 clinics in Southern California and the Central Coast, alongside research and medical education. The organization conducts pioneering research in oncology, transplantation, neurosurgery, and other specialties, having contributed to the development of numerous FDA-approved treatments.
Companies working in the same space as Sisu Pharma.
Frequently asked questions
- What does Sisu Pharma do?
- Sisu Pharma develops therapeutics targeting Heat Shock Factor 1 (HSF1), using its HI-LiTe platform to create selective HSF1 degraders for oncology and HSF1 activators for neurodegenerative diseases. Its compounds are aimed at therapy-resistant cancers and other difficult-to-treat diseases.
- Who founded Sisu Pharma?
- Sisu Pharma was founded by Sean E. O'Brien in 2019.
- How much funding has Sisu Pharma raised?
- Sisu Pharma has disclosed $1.7M raised across 1 round.
- Where is Sisu Pharma headquartered?
- Sisu Pharma is headquartered in Chapel Hill, US.